IsoTherapeutics Group is a radiopharmaceutical company that provides research and development services, including animal studies and early stage manufacturing for the purpose of aiding customers
and collaborators in the development of radionuclide-based drug and device products. Current collaborators include Molecular Imaging, PerkinElmer, MD Anderson Cancer Center, University of
Missouri-Columbia, Excel Diagnostics and Valco Instruments. The Company scientists, while formerly employed at The Dow Chemical Company, developed the commercial products QUADRAMET® and Iotrex®.
AMI has partnered with IsoTherapeutics Group, LLC of Angleton, TX on the manufacturing and preclinical development of Y-90 based brachytherapy. The first project between AMIC and IsoTherapeutics
focuses on AMIC’s Y-90 RadioGel™ device. IsoTherapeutics is developing and executing studies, under AMI guidance, in the manner the FDA has requested, with the end goal of FDA clearance for the
Y-90 RadioGel™ device.
“We are pleased to offer our services to AMI and look forward to a long and outstanding collaboration that will have a significant, positive impact on the commercialization efforts of the AMIC
Y-90 brachytherapy products,” stated R. Keith Frank, Ph.D., President and CEO of IsoTherapeutics Group.